Related Experiment Video
Updated: Jun 18, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime
Jose A Bazan1, Stanley I Martin, Kenneth M Kaye
1Division of Infectious Diseases, The Ohio State University Medical Center, N1129 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210, USA.
Abstract:
This article reviews the new beta-lactam (beta-lactam) antibiotics doripenem, ceftobiprole, and ceftaroline. It covers pharmacokinetic and pharmacodynamic properties, dosing, in vitro activities, safety, and clinical trial results. Doripenem (Doribax) has been approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections. At this writing, ceftobiprole is under review by the FDA for approval based on results of phase 3 clinical trials, whereas at least one phase 3 clinical trial of ceftaroline has been completed. The article also reviews recent data suggesting increased overall mortality with Cefepime (Maxipime) use compared with other beta-lactam antibiotics and the potential risk for neurotoxicity in the setting of renal failure.
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Development of Antibiotic Resistance
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibitors of Bacterial DNA Synthesis
